SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-035107
Filing Date
2023-12-21
Accepted
2023-12-21 16:30:19
Documents
13
Period of Report
2023-12-15
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pirs20231107_8k.htm   iXBRL 8-K 30132
  Complete submission text file 0001437749-23-035107.txt   165810

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pirs-20231215.xsd EX-101.SCH 3410
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pirs-20231215_def.xml EX-101.DEF 11808
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pirs-20231215_lab.xml EX-101.LAB 15859
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pirs-20231215_pre.xml EX-101.PRE 12023
7 EXTRACTED XBRL INSTANCE DOCUMENT pirs20231107_8k_htm.xml XML 2657
Mailing Address 225 FRANKLIN STREET 26TH FLOOR BOSTON MA 02110
Business Address 225 FRANKLIN STREET 26TH FLOOR BOSTON MA 02110 857-246-8998
PIERIS PHARMACEUTICALS, INC. (Filer) CIK: 0001583648 (see all company filings)

IRS No.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37471 | Film No.: 231505706
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)